AzTrials
AzTrials

Uterine ScarNCT03629028

Single or Double-layer Uterine Closure Techniques

A study testing Residual myometrium thickness, Niche Presence and Adjacent myometrium thickness in people with Uterine Scar and Cesarean Section Complications, run by Safak Baran Yilmaz at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

There are different surgical techniques of uterine closure during cesarean. A growing data has suggested that the closure technique has an effect on uterine scar healing. Residual myometrium thickness and uterine scar defect (niche) development seems to be related to the single or double layer closure of uterus. Read more about this study

Who is it for?
Ages 18 to 45 years, women onlyHealthy volunteers can take part
What is being tested?
Residual myometrium thickness, Niche Presence and Adjacent myometrium thickness
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
282 participants
Where
1 siteTurkey (Türkiye)
Study dates
18 Aug 2018to 10 Mar 2020
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Primary cesarean, singleton pregnancy,

Who cannot join

  • Multiple pregnancy, History of any uterine surgery, wound healing diseases (insulin dependent diabetes mellitus, rheumatoid arthritis, systemic lupus erythematous, inflammatory bowel disease)

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Baskent University Adana Seyhan Uygulama Hastanesi

    Adana

Other trials in Turkey (Türkiye)

About this study

Official title: Single or Double-layer Uterine Closure Techniques Following Cesarean: An Ongoing Debate

There are different surgical techniques of uterine closure during cesarean. A growing data has suggested that the closure technique has an effect on uterine scar healing. Residual myometrium thickness and uterine scar defect (niche) development seems to be related to the single or double layer closure of uterus. In that study, investigators will search for the effect of single or double layer closure of uterus during cesarean on the uterine scar defect.

Read the detailed description

Study design and participants This study will be assessed cesarean delivery (CD) patients who will admit to the Obstetrics and Gynecology Clinic of the Başkent University Adana Dr. Turgut Noyan Research and Application Center between July 2018 and September 2019. Specifically, participants will be singleton pregnancy patients between 18-45 years of age who will be in gestational weeks 24-41 and had not previously received any uterine operations such as CS or myomectomy. Patients with multiple pregnancies and/or chronic inflammatory diseases such as systemic lupus erythematosus, rheumatoid arthritis, and insulin-dependent diabetes mellitus will be excluded. All patients who meet the inclusion criteria will be randomized into two treatment groups (i.e., single- or double-layer closures).

This study was approved by Başkent University Institutional Review Board and Ethics Committee (Project no= KA18-71, Approval Date= 7/27/2018), and supported by Başkent University Research Fund. Patients who will agree to participate in the study will be informed about the purpose of the study before their operations, and each provided signed written consent.

Participants will be also assessed for maternal age, gravidity, parity, body mass index, smoking status, diabetes mellitus, hypertensive diseases of pregnancy, and medical history. Regardless of whether they had contractions before surgery, this study also will be determined patient CD indications, levels of cervical dilatation, and how CD will be established (i.e., elective or emergent).

Randomization and masking A table of random numbers is used as a simple randomization method for placing participants into the two treatment groups. The Research Randomizer website (https://www.randomizer.org/) was used to create this table. Before the intervention, the next envelope among a previously prepared, sealed, and the number-ordered stack will be opened by a nurse for each procedure.

Surgery technique Six operators will perform CD operations. Access to the abdomen will be achieved via Pfannenstiel incision, while the Kerr incision technique will be applied to the uterus for all patients. Patients in the single-layer group will be received uterus closures with locking, while patients in the double-layer group will be received uterus closures with locking in the first layer, but without locking and using the Lambert style in the second layer. The decidua will be deliberately excluded during all suturations. A synthetic absorbable suture material (Vicryl 1.0, Ethicon, Somerville, NJ, USA) will be used during all uterus closures, with corner stitches that will be applied to all patients. Additional suture usages and numbers will be reported only in cases of bleeding. Both uterine closure and whole operation times will be recorded by the respective operating room technicians. Finally, intravenous prophylactic antibiotics (2 g cefazolin sodium) and uterotonic medications (10 IU oxytocin) will be routinely applied during all CD procedures.

Follow-up Postoperative follow-ups will be completed in March 2020. All participants will be called after delivery and will be invited to complete sixth-month evaluations. However, participants who will experience post-CD pregnancies or uterine surgeries will be excluded. All remaining participants will be examined at six to nine months period after CD for niche presence in the scar region, niche measurements, scar shape, distance between niche and the external cervical os and residual myometrium thickness (RMT), and adjacent myometrium thicknesses (AMT). The distance between the niche and external os should be measured parallel to the top of the main niche, from the most distal niche point to external os. These examinations will be conducted by two experienced sonographers who will be blinded to clinical information regarding the closure technique. Procedures will be specifically completed using a 4-10 MHz transducer (E8C-RS micro convex endocavity probe, Voluson S6, GE, Milwaukee, US), ultrasonography, and through the saline infusion sonohysterography (SIS) method. The cervix will be first cleaned with povidone iodine while the patient will be on the gynecological examination table prior to ultrasonography. The SIS process then will be progressed toward the inside of the endometrial cavity by passing from the cervical os with an intrauterine insemination cannula (intrauterine insemination catheter, Wallace Artificial Insemination Catheter, Smiths Medical International Ltd., Ashford, Kent, UK). A sterile saline solution will be applied to sufficiently distend the cavity, while ultrasonography will be conducted via transvaginal probe. At this time, the presence of a hypoechogenic area with a depth of 2mm or deeper in the CD scar region within the endometrial cavity will be accepted as a niche. Niche dimensions will be determined via 3-axis measurements for depth, length, and width. Niche shape, distance to the external cervical os, RMT, and AMT will be evaluated. During these follow-ups, patients will be also asked about their menstruation processes and any experiences of cervical pain, menstruation pain, postmenstrual bleeding (PMB) in the form of spotting, and other abnormal bleeding patterns. Those who will experience bleeding for two days or more in the form of spotting after menstruation will be defined as PMB. Participants who will use intrauterine devices after CD and/or those who could not tolerate speculum application will be examined via transvaginal ultrasonography (TV USG).

Outcomes Primary outcomes will be considered niche presence and measurements, while secondary outcomes will be considered RMT, AMT, healing ratio, postmenstrual spotting, and dysmenorrhea.

Statistical analyses The sample size was calculated based on a study by Di Spiezio Sardo et al. (2017) titled Risk of Cesarean Scar Defect Following Single- vs Double-Layer Uterine Closure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Their study revealed niche formation rates for single- and double-layer closure types of 25% and 43%, respectively. Based on tools available at the Power and Sample Size website (http://powerandsamplesize.com/Calculators), the needed sample size was calculated at 141 for each treatment group with 90% power and 0.05 alpha error.

All data were statistically analyzed using the IBM SPSS 21.0 software. Categorical measurements will be presented as frequencies and percentages, while continuous measurements will be summarized as means and standard deviations (median and range when needed). Distributions will be checked and the student's t-test was will be used for variables meeting the parametric test assumptions when comparing the continuous measurements based on groups, while the Mann Whitney U test will be used for those that will not meet the parametric test assumptions. Finally, chi-square or Fisher's test statistics will be used to compare categorical variables. Statistical significance is set to 0.05 for all tests.

Being tested
Residual myometrium thickness, Niche Presence, Adjacent myometrium thickness, Niche Measurements (depth of niche, width of niche, length of niche)
Keywords
cesarean section, niche, isthmocele, uterine closure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Residual myometrium thicknessDiagnostic test

    The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.

  • Niche PresenceDiagnostic test

    The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.

  • Adjacent myometrium thicknessDiagnostic test

    The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.

  • Niche Measurements (depth of niche, width of niche, length of niche)Diagnostic test

    The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.

Study groups in NCT03629028
Study groupRoleWhat they receive
Single LayerActive comparatorDiagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
Receives: Diagnostic Test: Residual myometrium thickness; Diagnostic Test: Niche Presence; Diagnostic Test: Adjacent myometrium thickness; Diagnostic Test: Niche Measurements (depth of niche, width of niche, length of niche)
Double LayerActive comparatorDiagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
Receives: Diagnostic Test: Residual myometrium thickness; Diagnostic Test: Niche Presence; Diagnostic Test: Adjacent myometrium thickness; Diagnostic Test: Niche Measurements (depth of niche, width of niche, length of niche)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Niche Visualized by Saline Infusion Sonography

    The presence of niche in incision line visualized by saline infusion sonography

    Measured: 6 to 9 months

  2. Median Depth of Niche

    with saline infusion sonohysterography

    Measured: 6-9 months

  3. Median Length of Niche

    by saline infusion sonohysterography

    Measured: 6-9 months

  4. Median Width of Niche in Transverse Plane

    median width of niche in transverse plane by saline infusion sonohysterograhpy

    Measured: 6-9 months

Secondary outcomes (2)
  1. Residual Myometrium Thickness - 6 to 9 Months

    The residual myometrium thickness in incision line measured by saline infusion sonography

    Measured: 6 to 9 months

  2. Adjacent Myometrium Thickness

    Adjacent myometrium thickness out of incision line measured by saline infusion sonography

    Measured: 6 to 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2018
  2. Study start18 Aug 2018
  3. Primary completion18 Aug 2018
  4. Study completion10 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective Randomised Trial
Masking
None (open label)
Enrolment
282 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03629028
Sponsor's protocol ID
KA 18/71
Status last verified
Apr 2020
First submitted
9 Aug 2018
Last updated
1 May 2020
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Di Spiezio Sardo A, Saccone G, McCurdy R, Bujold E, Bifulco G, Berghella V. Risk of Cesarean scar defect following single- vs double-layer uterine closure: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2017 Nov;50(5):578-583. doi: 10.1002/uog.17401. Epub 2017 Oct 9.

    PubMed 28070914

Questions about this trial

What is this clinical trial studying?

A study testing Residual myometrium thickness, Niche Presence and Adjacent myometrium thickness in people with Uterine Scar and Cesarean Section Complications, run by Safak Baran Yilmaz at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 May 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Niche Visualized by Saline Infusion Sonography (time frame: 6 to 9 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03629028, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in